Neurogene to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:

Guggenheim Emerging Outlook: Biotech Summit 2026
Format: Management will participate in a fireside chat and investor meetings
Date: Thursday, February 12 at 9:00 a.m. ET

TD Cowen 46th Annual Health Care Conference
Format: Management will participate in a fireside chat and investor meetings
Date: Wednesday, March 4 at 10:30 a.m. ET

Leerink Global Healthcare Conference
Format: Management will participate in a fireside chat and investor meetings
Date: Monday, March 9 at 1:40 p.m. ET

Live webcasts of the fireside chats will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the events will also be available for a limited time.

About Neurogene

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit www.neurogene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205890359/en/

Company Contact:
Mike Devine
Executive Director, Corporate Communications
[email protected]

Investor Contact:
Argot Partners
[email protected]

Source: Neurogene Inc.

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• What Are AI-Based Memecoins? MemeToro, Virtuals Protocol And The Top AI Agents To Watch In 2026
• BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026